Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
03:50pm, Thursday, 31'st Oct 2024
Galapagos NV (NASDAQ:GLPG ) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO &
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
04:01pm, Wednesday, 30'th Oct 2024
Webcast presentation on October 31, 2024, at 1 3 :00 CET / 8:00 am ET, www.glpg.com
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
01:00am, Monday, 07'th Oct 2024
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Direct
SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected
Galapagos receives transparency notification from EcoR1 Capital
04:01pm, Monday, 30'th Sep 2024
Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Galapagos receives transparency notification from EcoR1 Capital
04:01pm, Monday, 16'th Sep 2024
Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Galapagos receives transparency notification from FMR LLC
04:01pm, Tuesday, 03'rd Sep 2024
Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
10:21am, Monday, 26'th Aug 2024
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
03:49pm, Friday, 23'rd Aug 2024
Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
08:45am, Friday, 23'rd Aug 2024
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA)
Galapagos receives transparency notification from FMR LLC
04:01pm, Tuesday, 20'th Aug 2024
Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript
01:25pm, Friday, 02'nd Aug 2024
Galapagos NV (NASDAQ:GLPG ) Q2 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Head of Investor Relations Paul Stoffels - Chair of the Board and Chief E
Galapagos reports half-year 2024 financial results and provides second quarter business update
04:01pm, Thursday, 01'st Aug 2024
Webcast presentation with management on 2 August 2024, at 14:00 CET / 8:00 AM ET, www.glpg.com
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
04:01pm, Thursday, 01'st Aug 2024
BridGene Eligible to Receive Up to $15 9 Million in Total Payments SAN JOSE, Calif. , Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for tra
